Search Results 2731-2740 of 17705 for rheumatoid arthritis

1. Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis - Mayo Clinic

   Patients must have adequate bone marrow function as defined by the following within 28 days prior to registration: ANC ≥ 1,000 cells/mcl without growth factor ...

2. Immunotherapy Clinical Trials - Mayo Clinic Research

   Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces ...

3. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

   ... Factor Xa inhibitors). Pregnant or nursing (lactating) women. Treatment with the following therapies within the specified time period: Monoclonal antibodies ...

4. Neoadjuvant Combination Targeted and Immunotherapy for Patients With High-Risk Stage III Melanoma - Mayo Clinic

   ... factor (TNF)-a agents) ≤2 weeks prior to registration, or anticipation of need for systemic immunosuppressive medication during the course of the study.

5. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   Participation eligibility · Absolute neutrophil count ≥ 1000/µl (no growth factor within 1 week of study drug administration; no pegylated growth factors within ...

6. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy - Mayo Clinic

   ... factor receptor 2 (HER2)-negative per. American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines (immunohistochemistry ...

7. Jordan D. Miller, PhD Cardiovascular Biology Heart valve disease, vascular biology, ectopic calcification

   enhancing neuroplasticity at the spinal cord, motoneuron, neuromuscular junction and muscle levels. • Two main trophic factor families are actively.

8. A Study to Create a Registry of Patients with Hypophosphatasia (HPP) - Mayo Clinic

   To avoid this confounding factor, a comparison between baseline disease manifestations prominent among treated versus untreated adult patients was limited ...

9. Back pain - Doctors and departments - Mayo Clinic

   Wenchun Qu, M.D., Ph.D. Physiatrist. Jacksonville, FL. Areas of focus: Regenerative medicine therapy, Ultrasound, Pain management, Back pain, Arthritis, Neck ...

10. Joint Replacement Revisions Clinical Trials - Mayo Clinic Research

    One factor that may cause failure of a total hip arthroplasty is an elevated level of these ions around the hip. A Study of Genes Responsible for Joint ...